+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Iron Requirements in Hemodialysis

      a , b

      Blood Purification

      S. Karger AG

      Iron, Hemodialysis, Anemia, Erythropoietin, Blood loss, Iron loss

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The correction of anemia in dialysis patients with erythropoietin (EPO) can be frustrated by insufficient iron. To address this effect, we preloaded candidate EPO patients with intravenous iron in the early 1990s. Preloading with 900–1,525 mg of iron yielded the following results: 70% of patients had increasing hematocrits (HCTs) without EPO, and 40% of patients had HCTs greater than 30%. Apparent lack of iron led to blood loss studies. Routes evaluated were blood sampling, dialyzer clotting, blood in the dialyzer circuit and postdialysis bleeding. Projected annual losses were between 2,516 and 5,126 ml, depending on circuit and posttreatment losses. In terms of red cell loss, the results are comparable to those in the early days of dialysis before the introduction of current technology. Extension of these studies to daily dialysis predicts possible losses with this 6 times a week therapy of between 4,663 and 9,884 ml per year.

          Related collections

          Author and article information

          Blood Purif
          Blood Purification
          S. Karger AG
          July 2004
          20 January 2004
          : 22
          : 1
          : 112-123
          aQuantitative Medical Systems, Inc., Emeryville, Calif., bUniversity of Tennessee, Memphis, Tenn., USA
          74931 Blood Purif 2004;22:112–123
          © 2004 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Figures: 10, Tables: 3, References: 6, Pages: 12
          Self URI (application/pdf): https://www.karger.com/Article/Pdf/74931

          Cardiovascular Medicine, Nephrology

          Iron, Iron loss, Blood loss, Erythropoietin, Anemia, Hemodialysis


          Comment on this article